As part of the Brigham and Women's Hospital Division of Cardiovascular Medicine, the CICL serves as a vibrant and productive research center for investigations related to cardiovascular imaging and outcomes in large clinical studies.

The CICL has worked on image analysis studies with a wide variety of sponsors, including the National Institutes of Health. The CICL ensures internal quality control and compliance with industry regulations for all studies. The CICL team also works closely with sponsors to ensure timely deliverables for each project. A selected list of prior and ongoing investigations is shown below.

Selected Prior and Ongoing Investigations and Sponsors

  • Aliskiren in Left Ventricular Hypertrophy Study (ALLAY) – Novartis

  • Aliskiren Observation of Heart Failure Treatment (ALOFT) – Novartis

  • A Safety and Efficacy Study of the CARILLION™ Mitral Contour System™ for the Treatment of Mitral Regurgitation (AMADEUS™) – Cardiac Dimensions

  • Atherosclerosis Risk In Communities Study (ARIC) – NIH/NHLBI

  • Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE) – Novartis

  • Hypoxia Inducible Factor I gene transfer study in patients with incomplete revascularization (CAD-HIF-006) – Genzyme

  • hemodynamics of CHronic Atrial pacing in the region of bachmannʼS bunddlE (CHASE) – Medtronic

  • Direct inhibition of δ protein kinase c Enzyme to Limit Total infarct size in Acute Myocardial Infarction (DELTA-MI) – Kai Pharmaceuticals

  • Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation (ENGAGE-AF/TIMI 48) – Daiichi Sankyo

  • Exforge Aggressive Control of Hypertension to Evaluate Efficacy in Diastolic Dysfunction (EXCEED) trial – Novartis

  • Cardiac structure and function in Fabryʼs Disease – response to Fabryzyme Therapy: Echocardiographic Analysis completed (FABRYS) – Genzyme

  • Herceptin Cardiomyopathy (H2338n) – NSABP/NCI and Genentech

  • the Healing and Early Afterload Reducing Therapy trial (HEART) – Hoechst-Marion Roussel

  • Imatinib in Pulmonary arterial hypertension, a Randomized, Efficacy Study (IMPRES) – Novartis

  • Multicenter Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) – Boston Scientific Corporation

  • Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) – Assistance Publique Hopitaux de Paris and Genzyme Corporation

  • Metabolic Efficiency with Ranolazine for Less Ischemia in Non-st elevation acute coronary syndromes (MERLIN) – TIMI group

  • An Open-Label, Multi-Center, Phase 3 Study Evaluating the Prognostic Usefulness of I123-mIBG Scintigraphy for Identifying Subjects with Heart Failure who will Experience an Adverse Cardiac Event (MBG 311 and MBG 312) – General Electric

  • Efficacy and Tolerability of Nebivolol Compared With Carvedilol in Patients with a Coronary Artery Disease and Stage I or II Hypertension (NEB-MD-06) – Forest Research Institute

  • Noninvasive Determinants of Left Ventricular Remodeling – American Heart Association

  • National Surgical Adjuvant Breast and bowel Project (NSABP) – NSABP

  • Effects of Dronedarone on Cardiac Geometry and Function in Patients With Atrial Fibrillation and Left Atrial Enlargement (ODYSSEUS) – Sanofi-Aventis

  • Safety and Efficacy Study of Omnitarg (Pertuzumab) (OMNITARG) – Genentech

  • Ohio Pacing post-Infarction Study (OPIS) – Guidant

  • Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) – Bristol-Myers Squibb

  • Hemodynamic Benefits of Optimized Dual Chamber Pacing vs. Intrinsic Conduction in Patients with Low Ejection Fraction (PACE/WAIT) – Medtronic

  • Efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction (PARAMOUNT) – Novartis

  • Prevention of Atrial fibrillation and Remodeling with Irbesartan Study (PARIS) – Sanofi-Synthelabo Recherche/Bristol Meyers Squibb

  • A Study of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Acid alpha-Glucosidase (rhGAA) Treatment in Patients older than 6 Months Old with Infantile-Onset Pompe Disease (POMPE) – Genzyme

  • Paricalcitol capsules benefits in Renal failure Induced cardiac Morbidity in subjects with chronic kidney disease stage 5 (PRIMO II). – Abbott Laboratories

  • Survival and Ventricular Enlargement Trial (SAVE) – Bristol-Myers

  • A Pilot Safety Study of the CARILLON™ Mitral Contour System™ for the Treatment of Mitral Regurgitation (TITAN™) – Cardiac Dimensions

  • Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) – NIH/NHLBI

  • The Valsartan In Acute Infarction Trial (VALIANT) – Novartis

  • Valsartan In Diastolic Dysfunction Trial (VALIDD) – Novartis

Recent CICL Publications

The CICL research group is comprised of faculty physicians, research fellows, imaging technicians, and project management staff. Each year, research fellows and faculty present their work at national and international scientific meetings and publish in high-impact cardiology and medical journals. All members of the CICL group benefit from the rich array of education, research, and training resources available at the Brigham and Women's Hospital, the Harvard Medical School, and campus-wide Harvard affiliated institutions. Since its founding in 1998, the CICL research group has published over 100 original articles.

To learn more about research and training opportunities at the CICL, please email Dr. Scott Solomon at ssolomon@partners.org.

Select Recent CICL Publications include:

Tamez H, Zoccali C, Packham D, Wenger J, Bhan I, Appelbaum E, Pritchett Y, Chang Y, Agarwal R, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Singh B, Zehnder D, Pachika A, Manning WJ, Shah A, Solomon SD, Thadhani R. Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J. 2012;164(6):902-909.

Kutyifa V, Solomon SD, Bourgoun M, Shah AM, Pouleur AC, Knappe D, McNitt S, Wang PJ, Merkely B, Pfeffer M, Moss AJ, Zareba W. Effects of Cardiac Resynchronization Therapy on Left Ventricular Mass and Wall Thickness in Mild Heart Failure Patients in MADIT-CRT. Heart Rhythm. 2012.

Shah AM, Bourgoun M, Narula J, Jacobson AF, Solomon SD. Influence of Ejection Fraction on the Prognostic Value of Sympathetic Innervation Imaging With Iodine-123 MIBG in Heart Failure. JACC Cardiovasc Imaging. 2012;5(11):1139-46.

Lam CS, Shah AM, Borlaug BA, Cheng S, Verma A, Izzo J, Oparil S, Aurigemma GP, Thomas JD, Pitt B, Zile MR, Solomon SD. Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency. Eur Heart J. 2012.

Platz E, Lattanzi A, Agbo C, Takeuchi M, Resnic FS, Solomon SD, Desai AS. Utility of lung ultrasound in predicting pulmonary and cardiac pressures. Eur J Heart Fail. 2012.

Pedrizzetti G, Kraigher-Krainer E, De Luca A, Caracciolo G, Mangual JO, Shah A, Toncelli L, Domenichini F, Tonti G, Galanti G, Sengupta PP, Narula J, Solomon S. Functional strain-line pattern in the human left ventricle. Phys Rev Lett. 2012;109(4):048103.

Siminiak T, Wu JC, Haude M, Hoppe UC, Sadowski J, Lipiecki J, Fajadet J, Shah AM, Feldman T, Kaye DM, Goldberg SL, Levy WC, Solomon SD, Reuter DG. Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN Trial. Eur J Heart Fail. 2012.

Vardeny O, Pouleur AC, Takeuchi M, Appelbaum E, Verma A, Prescott M, Smith B, Dahlof B, Solomon SD for the ALLAY Investigators. Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression. JRAAS. 2012.

Meris A, Amigoni M, Verma A, Thune JJ, Køber L, Velazquez E, McMurray JJ, Pfeffer MA, Califf R, Levine RA, Solomon SD; Valsartan in Acute Myocardial Infarction (VALIANT) Investigators. Mechanisms and Predictors of Mitral Regurgitation after High-Risk Myocardial Infarction. J Am Soc Echocardiogr. 2012.

Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J. Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO Randomized Clinical Trial. JAMA. 2012;307(7):674-84.

Brenyo A, Link MS, Barsheshet A, Moss AJ, Zareba W, Wang PJ, McNitt S, Huang D, Foster E, Estes M 3rd, Solomon SD, Goldenberg I. Cardiac resynchronization therapy reduces left atrial volume and the risk of atrial tachyarrhythmias in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy). J Am Coll Cardiol. 2011 Oct 11;58(16):1682-9.

Pouleur AC, Knappe D, Shah AM, Uno H, Bourgoun M, Foster E, McNitt S, Hall WJ, Zareba W, Goldenberg I, Moss AJ, Pfeffer MA, Solomon SD; for the MADIT-CRT Investigators. Relationship between improvement in left ventricular dyssynchrony and contractile function and clinical outcome with cardiac resynchronization therapy: the MADIT-CRT trial. Eur Heart J. 2011;32:1720-1729.

Knappe D, Pouleur AC, Shah AM, Cheng S, Uno H, Hall WJ, Bourgoun M, Foster E, Zareba W, Goldenberg I, McNitt S, Pfeffer MA, Moss AJ, Solomon SD; for the Multicenter Automatic Defibrillator Implantation Trial – Cardiac Resynchronization Therapy Investigators. Dyssynchrony, Contractile Function, and Response to Cardiac Resynchronization Therapy. Circ Heart Fail. 2011;4:433-440.

Solomon SD, Shin SH, Shah A, Skali H, Desai A, Kober L, Maggioni AP, Rouleau JL, Kelly RY, Hester A, McMurray JJ, Pfeffer MA; Aliskiren Study in Post-MI Patients to Reduce Remodeling (ASPIRE) Investigators. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J. 2011;32:1227-34.

Hung CL, Verma A, Uno H, Shin SH, Bouroun M, Hassanein AH, McMurray JJ, Velazquez EJ, Kober L, Pfeffer MA, Solomon SD for the VALIANT Investigators. Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction. J Am Coll Cardiol. 2010;56:1812-22.

Solomon SD, Foster E, Bourgoun M, Shah A, Viloria E, Brown M, Hall WJ, Pfeffer MA, Moss AJ for the MADIT-CRT Investigators. Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: MADIT-CRT. Circulation. 2010;122:985-92.

Shin SH, Hung CL, Hassanein AH, Verma A, Bourgoun M, Kober L, Ghali JK, Velazquez EJ, Califf R, Pfeffer MA, Solomon SD. Mechanical Dyssynchrony after Myocardial Infarction in Patients with Left Ventricular Dysfunction, Heart Failure, or Both. Circulation. 2010;121:1096-103.

Wu JC, Ho CY, Skali H, Abichandani R, Wilcox WR, Banikazemi M, Packman S, Sims K, Solomon SD. Cardiovascular Manifestations of Fabry Disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. Eur Heart J. 2010;31:1088-97.

Solomon SD, Verma A, Desai A, Hassanein A, Izzo J, Oparil S, Lacourciere Y, Lee J, Seifu Y, Hilkert R, Rocha R, Pitt B. Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension. 2010;55:241-8.

Moss AJ, Hall WJ, Cannom SD, Klein H, Brown MW, Daubert JP, Estes NAM, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W for the MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329-38.

Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif-Papst C, Smith BA, Dahlof B for the Aliskiren in left ventricular hypertrophy trial investigators. Effect of the direct renin inhibitor aliksiren, the angiotensin receptor blocker losartan, or both, on left ventricular mass in patients with hypertension and left ventricular hypertrophy.Circulation. 2009;119:530-7.

Meris A, Amigoni M, Uno H, Thune JJ, Verma A, Køber L, Bourgoun M, McMurray JJ, Velazquez EJ, Maggioni AP, Ghali J, Arnold JM, Zelenkofske S, Pfeffer MA, Solomon SD. Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo Study.Eur Heart J. 2009;30:56-65.

Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, LaCourcier Y, Hippler SE, Fields H, Naqvi TZ, Mulvagh SL, Arnold JMO, Thomas JD, Zile MR, Aurigemma MD for the Valsartan in Diastolic Dysfunction (VALIDD) Investigators. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial.Lancet. 2007;369:2079-87.

See full list of publications